Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Asset 3 (Galapagos NV)
- Development stage
- Preclinical
- Lead developer
- Galapagos
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Asset 3 is an investigational chimeric antigen receptor T-cell (CAR-T) therapy currently in the discovery phase, developed by Galapagos' CellPoint division. It is designed to target an undisclosed antigen for the treatment of solid tumors, specifically small-cell lung cancer (SCLC) and neuro-endocrine tumors (NETs). The program was part of Galapagos' portfolio utilizing a decentralized manufacturing platform intended to provide point-of-care CAR-T cell production. However, in October 2025, Galapagos announced plans to wind down the CellPoint division, leaving the future development status of this preclinical asset uncertain.
Beyond the preview
Go deeper on Asset 3 (Galapagos NV).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asset 3 (Galapagos NV).